{"id":"NCT02972359","sponsor":"Gr√ºnenthal GmbH","briefTitle":"Safety of Intravenous Neridronic Acid in CRPS","officialTitle":"Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-12-20","primaryCompletion":"2019-01-09","completion":"2019-01-09","firstPosted":"2016-11-23","resultsPosted":"2019-11-04","lastUpdate":"2019-11-21"},"enrollment":580,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Complex Regional Pain Syndrome"],"interventions":[{"type":"DRUG","name":"Neridronic acid","otherNames":[]}],"arms":[{"label":"Neridronic acid","type":"EXPERIMENTAL"}],"summary":"The aim of this trial was to investigate the safety of intravenous neridronic acid in patients with complex regional pain syndrome (CRPS).\n\nThe trial was divided into 3 periods: a 60-day enrollment period, a treatment period consisting of 4 infusions over 10 days, and a follow-up period of approximately 50 weeks (with visits at Week 2, Week 6, Week 12, Week 26, Week 39, and Week 52).","primaryOutcome":{"measure":"Number of Participants With Occurrence of Any Treatment Emergent Adverse Event (TEAE)","timeFrame":"Day 1 to Week 52","effectByArm":[{"arm":"Neridronic Acid","deltaMin":277,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":5},"locations":{"siteCount":46,"countries":["United States","Germany"]},"refs":{"pmids":["19414839"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":316},"commonTop":["Headache","Myalgia","Nausea","Fatigue","Condition aggravated"]}}